PMID- 37783646
OWN - NLM
STAT- MEDLINE
DCOM- 20231127
LR  - 20240416
IS  - 1879-114X (Electronic)
IS  - 0149-2918 (Linking)
VI  - 45
IP  - 11
DP  - 2023 Nov
TI  - Use of Silica Nanoparticles for Drug Delivery in Cardiovascular Disease.
PG  - 1060-1068
LID - S0149-2918(23)00321-1 [pii]
LID - 10.1016/j.clinthera.2023.08.017 [doi]
AB  - PURPOSE: Cardiovascular disease (CVD) is the leading cause of death worldwide. 
      The current CVD therapeutic drugs require long-term treatment with high doses, 
      which increases the risk of adverse effects while offering only marginal 
      treatment efficacy. Silica nanoparticles (SNPs) have been proven to be an 
      efficient drug delivery vehicle for numerous diseases, including CVD. This 
      article reviews recent progress and advancement in targeted delivery for drugs 
      and diagnostic and theranostic agents using silica nanoparticles to achieve 
      therapeutic efficacy and improved detection of CVD in clinical and preclinical 
      settings. METHODS: A search of PubMed, Scopus, and Google Scholar databases from 
      1990 to 2023 was conducted. Current clinical trials on silica nanoparticles were 
      identified through ClinicalTrials.gov. Search terms include silica nanoparticles, 
      cardiovascular diseases, drug delivery, and therapy. FINDINGS: Silica 
      nanoparticles exhibit biocompatibility in biological systems, and their shape, 
      size, surface area, and surface functionalization can be customized for the safe 
      transport and protection of drugs in blood circulation. These properties also 
      enable effective drug uptake in specific tissues and controlled drug release 
      after systemic, localized, or oral delivery. A range of silica nanoparticles have 
      been used as nanocarrier for drug delivery to treat conditions such as 
      atherosclerosis, hypertension, ischemia, thrombosis, and myocardial infarction. 
      IMPLICATIONS: The use of silica nanoparticles for drug delivery and their ongoing 
      development has emerged as a promising strategy to improve the effectiveness of 
      drugs, imaging agents, and theranostics with the potential to revolutionize the 
      treatment of CVD.
CI  - Copyright (c) 2023 Elsevier Inc. All rights reserved.
FAU - Kirla, Haritha
AU  - Kirla H
AD  - Targeted Drug Delivery, Imaging & Therapy Laboratory, Harry Perkins Institute of 
      Medical Research, QEII Medical Centre, Nedlands, Western Australia, Australia; 
      Chemistry and Physics, College of Science, Health, Engineering and Education, 
      Murdoch University, Western Australia, Australia. Electronic address: 
      haritha.kirla@perkins.org.au.
FAU - Henry, David J
AU  - Henry DJ
AD  - Chemistry and Physics, College of Science, Health, Engineering and Education, 
      Murdoch University, Western Australia, Australia.
FAU - Jansen, Shirley
AU  - Jansen S
AD  - Targeted Drug Delivery, Imaging & Therapy Laboratory, Harry Perkins Institute of 
      Medical Research, QEII Medical Centre, Nedlands, Western Australia, Australia; 
      Curtin Health Innovation Research Institute and Curtin Medical School, Curtin 
      University, Perth, Western Australia, Australia; Heart & Vascular Research 
      Institute, Harry Perkins Institute of Medical Research, Nedlands, Western 
      Australia, Australia; Department of Vascular and Endovascular Surgery, Sir 
      Charles Gairdner Hospital, Nedlands, Western Australia, Australia.
FAU - Thompson, Peter L
AU  - Thompson PL
AD  - Heart & Vascular Research Institute, Harry Perkins Institute of Medical Research, 
      Nedlands, Western Australia, Australia.
FAU - Hamzah, Juliana
AU  - Hamzah J
AD  - Targeted Drug Delivery, Imaging & Therapy Laboratory, Harry Perkins Institute of 
      Medical Research, QEII Medical Centre, Nedlands, Western Australia, Australia; 
      Curtin Health Innovation Research Institute and Curtin Medical School, Curtin 
      University, Perth, Western Australia, Australia; Heart & Vascular Research 
      Institute, Harry Perkins Institute of Medical Research, Nedlands, Western 
      Australia, Australia. Electronic address: juliana.hamzah@perkins.org.au.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Review
DEP - 20231001
PL  - United States
TA  - Clin Ther
JT  - Clinical therapeutics
JID - 7706726
RN  - 7631-86-9 (Silicon Dioxide)
RN  - 0 (Pharmaceutical Preparations)
SB  - IM
MH  - Humans
MH  - *Cardiovascular Diseases/drug therapy
MH  - Silicon Dioxide
MH  - Drug Delivery Systems/methods
MH  - *Nanoparticles/therapeutic use
MH  - Pharmaceutical Preparations
OTO - NOTNLM
OT  - Atherosclerosis
OT  - Cardiovascular disease
OT  - Drug delivery
OT  - Silica nanoparticles
COIS- Declaration of Competing Interest The authors have indicated that they have no 
      other conflicts of interest with regard to the content of this article.
EDAT- 2023/10/03 00:42
MHDA- 2023/11/27 12:43
CRDT- 2023/10/02 21:59
PHST- 2023/05/15 00:00 [received]
PHST- 2023/08/22 00:00 [revised]
PHST- 2023/08/24 00:00 [accepted]
PHST- 2023/11/27 12:43 [medline]
PHST- 2023/10/03 00:42 [pubmed]
PHST- 2023/10/02 21:59 [entrez]
AID - S0149-2918(23)00321-1 [pii]
AID - 10.1016/j.clinthera.2023.08.017 [doi]
PST - ppublish
SO  - Clin Ther. 2023 Nov;45(11):1060-1068. doi: 10.1016/j.clinthera.2023.08.017. Epub 
      2023 Oct 1.